| David Poulsen, MD | |
|
1410 May St, Hood River, OR 97031 | |
| (541) 386-1399 | |
| (541) 386-7067 |
| Full Name | David Poulsen |
|---|---|
| Gender | Male |
| Speciality | Ophthalmology |
| Experience | 11 Years |
| Location | 1410 May St, Hood River, Oregon |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1346685633 | NPI | - | NPPES |
| 1346685633 | Medicaid | CA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207W00000X | Ophthalmology | A146507 (California) | Secondary |
| 207W00000X | Ophthalmology | MD192975 (Oregon) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Providence Hood River Memorial Hospital | Hood river, OR | Hospital |
| Skyline Hospital | White salmon, WA | Hospital |
| Ohsu Hospital And Clinics | Portland, OR | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Oregon Health And Sciences University/university Medical Group | 4880760107 | 1485 |
| Oregon Health And Sciences University/university Medical Group | 4880760107 | 1485 |
News Archive
If 22 million Americans lose their health care coverage by 2026 under the GOP Senate's plan to repeal and replace the Affordable Care Act, how many people could die? The question is at the heart of the debate raging in Washington, D.C., but has been difficult to answer.
Zyngenia, Inc., a privately held biotherapeutics company focused on next-generation antibody drug development, announced today the completion of a $15 million Series A financing extension from New Enterprise Associates (NEA), one of the world's leading venture capital firms. The capital will be used to continue to rapidly progress Zyngenia's pipeline of Zybodies™, which are novel, multi-specific, antibody-based molecules that address two or more biological targets with a single protein drug.
Synthon Biopharmaceuticals, a subsidiary of specialty pharma company Synthon, has reported promising results with its lead program of antibody-drug conjugates (ADCs).
Two prominent microbiologists have launched a new peer-reviewed publication focusing on microbiome research in environmental, agricultural, and biomedical areas. Eric Wommack, from the University of Delaware's College of Earth, Ocean and Environment and Jacques Ravel, from the University of Maryland School of Medicine's Institute for Genome Sciences are the Editors-in-Chief of Microbiome, a BioMed Central (BMC) publication, which launched its first issue this week.
› Verified 6 days ago
| Entity Name | University Professional Services |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1376709535 PECOS PAC ID: 4880760107 Enrollment ID: O20080910000013 |
News Archive
If 22 million Americans lose their health care coverage by 2026 under the GOP Senate's plan to repeal and replace the Affordable Care Act, how many people could die? The question is at the heart of the debate raging in Washington, D.C., but has been difficult to answer.
Zyngenia, Inc., a privately held biotherapeutics company focused on next-generation antibody drug development, announced today the completion of a $15 million Series A financing extension from New Enterprise Associates (NEA), one of the world's leading venture capital firms. The capital will be used to continue to rapidly progress Zyngenia's pipeline of Zybodies™, which are novel, multi-specific, antibody-based molecules that address two or more biological targets with a single protein drug.
Synthon Biopharmaceuticals, a subsidiary of specialty pharma company Synthon, has reported promising results with its lead program of antibody-drug conjugates (ADCs).
Two prominent microbiologists have launched a new peer-reviewed publication focusing on microbiome research in environmental, agricultural, and biomedical areas. Eric Wommack, from the University of Delaware's College of Earth, Ocean and Environment and Jacques Ravel, from the University of Maryland School of Medicine's Institute for Genome Sciences are the Editors-in-Chief of Microbiome, a BioMed Central (BMC) publication, which launched its first issue this week.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| David Poulsen, MD 1410 May St, Hood River, OR 97031-1347 Ph: (541) 386-1399 | David Poulsen, MD 1410 May St, Hood River, OR 97031 Ph: (541) 386-1399 |
News Archive
If 22 million Americans lose their health care coverage by 2026 under the GOP Senate's plan to repeal and replace the Affordable Care Act, how many people could die? The question is at the heart of the debate raging in Washington, D.C., but has been difficult to answer.
Zyngenia, Inc., a privately held biotherapeutics company focused on next-generation antibody drug development, announced today the completion of a $15 million Series A financing extension from New Enterprise Associates (NEA), one of the world's leading venture capital firms. The capital will be used to continue to rapidly progress Zyngenia's pipeline of Zybodies™, which are novel, multi-specific, antibody-based molecules that address two or more biological targets with a single protein drug.
Synthon Biopharmaceuticals, a subsidiary of specialty pharma company Synthon, has reported promising results with its lead program of antibody-drug conjugates (ADCs).
Two prominent microbiologists have launched a new peer-reviewed publication focusing on microbiome research in environmental, agricultural, and biomedical areas. Eric Wommack, from the University of Delaware's College of Earth, Ocean and Environment and Jacques Ravel, from the University of Maryland School of Medicine's Institute for Genome Sciences are the Editors-in-Chief of Microbiome, a BioMed Central (BMC) publication, which launched its first issue this week.
› Verified 6 days ago
Dr. Nathaniel James Gebhard, M.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 1410 May St, Hood River, OR 97031 Phone: 541-386-1399 | |
Hillary Chisholm Stiefel, M.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 1410 May St, Hood River, OR 97031 Phone: 541-386-1399 Fax: 541-386-7067 |